Miyoshi Yasuo相关文献与解析，生知库 | 链接生命科学的每一步

Takahashi, Masato; Mukai, Hirofumi; Takano, Toshimi; Tsugawa, Koichiro; Inoue, Kenichi; Itoh, Mitsuya; Watanabe, Junichiro; Tanabe, Yuko; Yamamoto, Naohito; Miyoshi, Yasuo; Watanabe, Kenichi; Mukohara, Toru; Kong, Yibin; Shimura, Masashi; Beca, Francisco; Schmid, Peter; Iwata, Hiroji

肿瘤

肿瘤免疫

乳腺癌

发表日期：2026

文献求助收藏

Prognostic significance of peripheral myeloid-derived suppressor cells in advanced breast cancer

外周血髓系来源抑制细胞在晚期乳腺癌中的预后意义

期刊:Breast Cancer

影响因子:2.9

doi:10.1007/s12282-026-01831-w

Kanaoka, Haruka; Nagahashi, Masayuki; Tsuchida, Junko; Kuroiwa, Mamiko; Urano, Sayaka; Komatsu, Miki; Yoshida, Shoko; Oshiro, Aoi; Sugimoto, Gen; Mitsuyoshi, Ayumu; Togashi, Yusa; Hattori, Akira; Higuchi, Tomoko; Nishimukai, Arisa; Shimoda, Masafumi; Miyoshi, Yasuo

An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia.

基于丙烯醛的药物递送系统可在不引起淋巴细胞减少的情况下，实现乳腺癌肿瘤特异性鞘氨醇-1-磷酸靶向治疗

期刊:Cancer Research Communications

影响因子:3.3

doi:10.1158/2767-9764.CRC-25-0023

Nagahashi Masayuki, Komatsu Miki, Urano Sayaka, Kuroiwa Mamiko, Takahashi Yuria, Morimoto Koji, Pradipta Ambara R, Tanaka Katsunori, Miyoshi Yasuo

Targeting Interleukin-6 as a Novel Strategy to Overcome Eribulin Resistance in Breast Cancer

以白细胞介素-6为靶点，克服乳腺癌中艾立布林耐药性的新策略

期刊:Cancer Medicine

影响因子:3.1

doi:10.1002/cam4.71273

Hattori, Akira; Nagahashi, Masayuki; Komatsu, Miki; Urano, Sayaka; Kuroiwa, Mamiko; Matsushita, Yosuke; Katagiri, Toyomasa; Shimoda, Masafumi; Miyoshi, Yasuo

The cytokine profile correlates with less tumor-infiltrating lymphocytes in luminal A breast cancer

细胞因子谱与管腔A型乳腺癌中肿瘤浸润淋巴细胞减少相关

期刊:Breast Cancer Research and Treatment

影响因子:3

doi:10.1007/s10549-024-07492-7

Ishikawa, Eri; Watanabe, Takahiro; Kihara, Takako; Kuroiwa, Mamiko; Komatsu, Miki; Urano, Sayaka; Nagahashi, Masayuki; Hirota, Seiichi; Miyoshi, Yasuo

Development and internal validation of a predictive model of overall and progression-free survival in eribulin-treated patients with breast cancer based on baseline peripheral blood parameters

基于基线外周血参数，建立并内部验证接受艾立布林治疗的乳腺癌患者的总生存期和无进展生存期预测模型

期刊:Breast Cancer

影响因子:2.9

doi:10.1007/s12282-025-01678-7

Natori, Keiko; Igeta, Masataka; Morimoto, Takashi; Nagahashi, Masayuki; Akashi-Tanaka, Sadako; Daimon, Takashi; Miyoshi, Yasuo

Clinical utility of tumor-infiltrating lymphocyte evaluation by two different methods in breast cancer patients treated with neoadjuvant chemotherapy

两种不同方法评估肿瘤浸润淋巴细胞在接受新辅助化疗的乳腺癌患者中的临床应用价值

期刊:Breast Cancer

影响因子:2.9

doi:10.1007/s12282-025-01665-y

Nagahashi, Masayuki; Ishikawa, Eri; Nagai, Takahiro; Kanaoka, Haruka; Oshiro, Aoi; Togashi, Yusa; Hattori, Akira; Tsuchida, Junko; Higuchi, Tomoko; Nishimukai, Arisa; Murase, Keiko; Takatsuka, Yuichi; Kihara, Takako; Ling, Yiwei; Okuda, Shujiro; Hirota, Seiichi; Miyoshi, Yasuo

Clinical implications of peripheral blood biomarkers in patients with advanced breast cancer treated with trastuzumab emtansine and trastuzumab deruxtecan

曲妥珠单抗-美坦新和曲妥珠单抗-德鲁替康治疗晚期乳腺癌患者外周血生物标志物的临床意义

期刊:International Journal of Clinical Oncology

影响因子:2.8

doi:10.1007/s10147-025-02768-4

Togashi, Yusa; Nagahashi, Masayuki; Oshiro, Aoi; Sugimoto, Gen; Mitsuyoshi, Ayumu; Kanaoka, Haruka; Hattori, Akira; Tsuchida, Junko; Higuchi, Tomoko; Nishimukai, Arisa; Miyoshi, Yasuo

Olanzapine for nausea and vomiting in people with breast cancer treated with trastuzumab deruxtecan: plain language summary of the ERICA study

奥氮平用于治疗接受曲妥珠单抗德鲁替康治疗的乳腺癌患者的恶心和呕吐：ERICA 研究的简明语言摘要

期刊:Future Oncology

影响因子:2.6

doi:10.1080/14796694.2025.2566329

Sakai, Hitomi; Tsurutani, Junji; Ozaki, Yukinori; Ishiguro, Hiroshi; Nozawa, Kazuki; Yamanaka, Takashi; Aogi, Kenjiro; Matsumoto, Koji; Iwasa, Tsutomu; Tokiwa, Mariko; Tsuneizumi, Michiko; Miyoshi, Yasuo; Kitagawa, Chiyoe; Yamamoto, Mitsugu; Takano, Yuko; Imamura, Chiyo K; Chiba, Yasutaka; Takiguchi, Daisuke; Ezumi, Takayuki; Takano, Toshimi

Germline variants detected by multigene panel testing in patients with suspected hereditary breast cancer

在疑似遗传性乳腺癌患者中，通过多基因检测发现的种系变异

期刊:Surgery Today

影响因子:1.6

doi:10.1007/s00595-025-02994-3

Togashi, Yusa; Nagahashi, Masayuki; Kashima, Mina; Okada, Chiho; Kinjo, Chinatsu; Miyazaki, Ayako; Ueda, Mako; Tsubamoto, Hiroshi; Sawai, Hideaki; Miyoshi, Yasuo

Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis

帕博利珠单抗治疗早期三阴性乳腺癌：KEYNOTE-522 日本亚组分析

Prognostic significance of peripheral myeloid-derived suppressor cells in advanced breast cancer

外周血髓系来源抑制细胞在晚期乳腺癌中的预后意义

An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia.

基于丙烯醛的药物递送系统可在不引起淋巴细胞减少的情况下，实现乳腺癌肿瘤特异性鞘氨醇-1-磷酸靶向治疗

Targeting Interleukin-6 as a Novel Strategy to Overcome Eribulin Resistance in Breast Cancer

以白细胞介素-6为靶点，克服乳腺癌中艾立布林耐药性的新策略

The cytokine profile correlates with less tumor-infiltrating lymphocytes in luminal A breast cancer

细胞因子谱与管腔A型乳腺癌中肿瘤浸润淋巴细胞减少相关

Development and internal validation of a predictive model of overall and progression-free survival in eribulin-treated patients with breast cancer based on baseline peripheral blood parameters

基于基线外周血参数，建立并内部验证接受艾立布林治疗的乳腺癌患者的总生存期和无进展生存期预测模型

Clinical utility of tumor-infiltrating lymphocyte evaluation by two different methods in breast cancer patients treated with neoadjuvant chemotherapy

两种不同方法评估肿瘤浸润淋巴细胞在接受新辅助化疗的乳腺癌患者中的临床应用价值

Clinical implications of peripheral blood biomarkers in patients with advanced breast cancer treated with trastuzumab emtansine and trastuzumab deruxtecan

曲妥珠单抗-美坦新和曲妥珠单抗-德鲁替康治疗晚期乳腺癌患者外周血生物标志物的临床意义

Olanzapine for nausea and vomiting in people with breast cancer treated with trastuzumab deruxtecan: plain language summary of the ERICA study

奥氮平用于治疗接受曲妥珠单抗德鲁替康治疗的乳腺癌患者的恶心和呕吐：ERICA 研究的简明语言摘要

Germline variants detected by multigene panel testing in patients with suspected hereditary breast cancer

在疑似遗传性乳腺癌患者中，通过多基因检测发现的种系变异